{"filings":[{"id":98522,"accession_number":"0001376474-26-000347","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q4 revenue up 5% to $7.65M, EPS $1.02; declares $1.00 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $7.65M (+5% YoY); product sales up 6%, contract R&D down 19%.","Q4 net income $4.93M ($1.02 EPS) vs $3.89M ($0.80 EPS) in prior-year quarter.","Fiscal 2026 revenue $26.3M (+1.8%); net income $15.2M ($3.14 EPS) vs $15.1M ($3.11).","Quarterly dividend $1.00 per share, payable May 29, 2026 to holders of record May 18, 2026.","CEO cites strong revenue and earnings growth for second consecutive quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":3.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":26331218.0,"consensus_period":"2026-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114056,"accession_number":"0001376474-26-000058","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE reports Q3 revenue up 23% to $6.22M, EPS $0.70 (+11% YoY); declares $1.00 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $6.22M, up 23% from $5.06M; product sales +16%, contract R&D +335%.","Net income $3.38M ($0.70 diluted EPS) vs $3.05M ($0.63) prior-year quarter.","First nine months revenue $18.7M (+0.4%); net income $10.3M ($2.12 EPS), down 8% YoY.","Quarterly dividend of $1.00 per share payable Feb 27, 2026 to holders of record Feb 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":18676412.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130447,"accession_number":"0001376474-25-000978","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K/A","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NVE extends Abbott supply agreement through 2027 with pricing increases for 2026-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 12 to Supplier Partnering Agreement with Pacesetter (Abbott) executed Dec 12, 2025.","Term extended through December 31, 2027; pricing for 2026 and 2027 increased (amounts redacted).","Parties agree to work on stabilizing costs and aligning pricing beyond 2027.","Agreement governs supply of sensor products; Abbott is a key customer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130448,"accession_number":"0001376474-25-000856","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q2 revenue down 6% to $6.35M; EPS $0.68 vs $0.83; declares $1.00 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.35M, down 6% YoY; product sales +1%, contract R&D -68%.","Net income $3.31M ($0.68 diluted EPS) vs $4.03M ($0.83) in prior-year quarter.","Board approves quarterly dividend of $1.00/share, payable Nov 28 to holders of record Nov 3.","CEO cites 4% sequential revenue increase driven by distributor and non-defense sales.","First-half FY2026 revenue $12.5M (-8% YoY); net income $6.89M ($1.42 EPS) vs $8.12M ($1.68)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":12451636.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147010,"accession_number":"0001376474-25-000737","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NVE shareholders elect all five director nominees and approve executive pay and auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Glarner, Baker, Hollister, Bracke, Wei each received >2.98M votes with minimal withhold.","Advisory vote on named executive officer compensation passed: 3,171,573 for, 87,852 against, 10,637 abstain.","Ratification of Boulay PLLP as auditor for FY ending March 2026 passed: 3,871,548 for, 2,794 against, 11,171 abstain.","Meeting had quorum with 4,837,166 shares represented; all incumbent directors attended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147009,"accession_number":"0001376474-25-000657","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q1 revenue down 10% to $6.10M; EPS $0.74 vs $0.85; declares $1.00 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.10M (down 10% YoY), net income $3.58M (down 13%); diluted EPS $0.74.","Product sales fell 11%, partially offset by 17% increase in contract R&D revenue.","Quarterly dividend of $1.00/share, payable Aug 29, 2025 to holders of record Aug 4, 2025.","CEO cites strong revenue and earnings despite decrease in defense product sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":6104644.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165519,"accession_number":"0001376474-25-000436","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q4 revenue up 3% to $7.27M, EPS $0.80; full-year revenue down 13%; $1.00 dividend declared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $7.27M (+3% YoY); net income $3.89M ($0.80 EPS) vs $3.81M ($0.79).","Full-year FY2025 revenue $25.9M (-13% YoY); net income $15.1M ($3.11 EPS) vs $17.1M ($3.54).","Q4 product sales -1% YoY, but contract R&D revenue surged 558% offsetting decline.","Quarterly dividend of $1.00/share declared, payable May 30, 2025 to holders of record May 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":3.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":25874694.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183159,"accession_number":"0001376474-25-000205","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K/A","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NVE extends supply agreement with Abbott through Dec 2025; 2025 price increases on three part numbers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 11 extends Supplier Partnering Agreement term to December 31, 2025.","Pricing increases for three part numbers (1071000-001, 100101124, 100127071) effective for shipments after Dec 31, 2024; specific prices redacted as confidential.","New Section 10.9 adds trade controls representations and warranties regarding sanctions, sanctioned areas, and sub-supplier compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183160,"accession_number":"0001376474-25-000100","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q3 revenue down 25% to $5.06M, net income falls 27% to $0.63 EPS; $1.00 dividend declared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $5.06M, down 25% YoY; product sales fell 22% and contract R&D revenue dropped 74%.","Q3 net income $3.05M ($0.63 diluted EPS), vs $4.18M ($0.87 EPS) a year ago.","First nine months revenue $18.6M (-18% YoY); net income $11.2M ($2.31 EPS), down 16%.","Board approved $1.00 per share quarterly dividend, payable Feb 28, 2025 to holders of record Feb 3, 2025.","CEO Dan Baker cited challenging industry conditions for the sales decline."],"consensus_eps_estimate":null,"consensus_eps_actual":2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":18604979.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199731,"accession_number":"0001376474-24-000647","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K/A","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NVE extends office/manufacturing lease to May 2031 with escalating rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease extended 62 months, new expiration May 31, 2031 (originally March 31, 2026).","Monthly base rent rises from $15,416.24 to $17,214.21 on April 1, 2026, with annual increases.","Free base rent granted for April and May 2026.","$100,000 improvement allowance from landlord, subject to conditions and completion deadlines.","Tenant has option to extend lease five more years; must exercise by June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199732,"accession_number":"0001376474-24-000613","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q2 revenue down 5% to $6.76M; EPS $0.83 vs $0.98; declares $1.00 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue for Q2 FY2025: $6.76M, down 5% from $7.13M; product sales fell 14%, contract R&D surged 3,950%.","Net income for Q2: $4.03M ($0.83 diluted EPS) vs $4.72M ($0.98) prior year, down 15%.","First-half FY2025 revenue: $13.5M (down 15%); net income $8.12M ($1.68 EPS) vs $9.13M ($1.89).","Board declared quarterly cash dividend of $1.00 per share, payable Nov 29, 2024 to holders of record Nov 4, 2024.","CEO cited 'solid earnings despite slow industry recovery'; stock ticker NVEC listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":13541934.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215751,"accession_number":"0001376474-24-000393","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NVE shareholders elect all five directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Glarner (2.78M for), Baker (3.06M), Hollister (2.85M), Bracke (3.05M), Wei (3.06M).","Advisory vote on named executive officer compensation passed: 3,015,808 for, 89,586 against.","Boulay PLLP ratified as auditor for FY ending March 2025: 3,759,285 for, 6,099 against.","Total shares entitled to vote: 4,833,676; majority represented at meeting.","No solicitation in opposition; all incumbent directors attended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215750,"accession_number":"0001376474-24-000322","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE reports Q1 revenue down 23% to $6.78M, EPS $0.85 vs $0.91 prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.78M, down 23% YoY; product sales fell 24%, contract R&D up 28%.","Net income $4.10M ($0.85 diluted EPS) vs $4.40M ($0.91) prior year, down 7%.","Board approved $1.00 per share quarterly dividend, payable Aug 30, record July 29.","CEO cites solid earnings despite challenging industry environment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":6783244.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235163,"accession_number":"0001376474-24-000235","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"NVE director Richard Kramp dies; Dr. Kelly Wei elected to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Richard W. Kramp passed away May 2, 2024 after an illness; served on NVE board since 2014.","Dr. Kelly Wei elected to board effective May 13, 2024 to fill unexpired term ending at 2024 annual meeting.","Wei is VP of Corporate Strategy at Medtronic, appointed to Compensation and Nominating committees.","Board determined Wei is independent under NASDAQ Listing Rule 5605(a)(2) and SEC regulations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235162,"accession_number":"0001376474-24-000213","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q4 revenue $7.08M (-45%), EPS $0.79; FY revenue $29.8M (-22%); declares $1.00 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $7.08M (-45% YoY); net income $3.81M ($0.79 EPS) down 54%.","FY2024 revenue $29.8M (-22% YoY); net income $17.1M ($3.54 EPS) down 25%.","Product sales fell 21% in FY; contract R&D revenue decreased 45%.","$1.00/share dividend approved; payable May 31, 2024, record May 13, 2024.","CEO says solid earnings despite semiconductor industry downturn."],"consensus_eps_estimate":null,"consensus_eps_actual":3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":29804179.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252981,"accession_number":"0001376474-24-000039","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"NVE Q3 revenue down 9% to $6.76M; net income down 1% to $4.18M; declares $1/share dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue for quarter ended Dec 31, 2023: $6.76M, down 9% vs $7.40M prior year. Product sales down 12%; contract R&D up 94%.","Net income $4.18M ($0.87 EPS) vs $4.23M ($0.88 EPS) prior year.","Nine-month revenue $22.7M (down 11%); net income $13.3M ($2.75 EPS) vs $14.5M ($2.99 EPS).","Quarterly cash dividend of $1.00 per share, payable Feb 28, 2024 to holders of record Jan 29, 2024.","CEO cites decrease in defense-related product sales and semiconductor downturn."],"consensus_eps_estimate":null,"consensus_eps_actual":2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":22720950.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252980,"accession_number":"0001376474-24-000002","cik":724910,"company_name":"NVE CORP /NEW/","ticker":"NVEC","form_type":"8-K/A","filed_at":"2024-01-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NVE extends Abbott supply pact through Dec 2024 with price increases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 10 extends Supplier Partnering Agreement with Abbott subsidiary Pacesetter through December 31, 2024.","Pricing increased for three part numbers (1071000-001, 100101124, 100127071) effective for shipments after Dec 31, 2023; specific amounts redacted.","Amendment dated December 7, 2023, fully executed and received by NVE on January 2, 2024.","Agreement originally effective Jan 1, 2006; Amendment No. 10 supersedes certain prior amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":455806146.1810666,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}